2019
The federal plan for health science and technology’s response to the opioid crisis: understanding sex and gender differences as part of the solution is overlooked
Becker JB, Mazure CM. The federal plan for health science and technology’s response to the opioid crisis: understanding sex and gender differences as part of the solution is overlooked. Biology Of Sex Differences 2019, 10: 3. PMID: 30616693, PMCID: PMC6322277, DOI: 10.1186/s13293-018-0215-5.Peer-Reviewed Original ResearchConceptsOpioid crisisClinical care providersCurrent opioid epidemicNeurobiology of painGender-specific treatmentGender differencesNeonatal exposureOpioid useOpioid epidemicOpioid addictionCare providersEpidemiological dataPrevention strategiesHealth SciencesGender-based treatmentSuccessful responseSexPrevention implicationsReportTreatmentAddictionFurther researchResponseOpioidsPain
2010
Examining antidepressant drug response by smoking status: why is it important and how often is it done?
Weinberger AH, McKee SA, Picciotto MR, Mazure CM. Examining antidepressant drug response by smoking status: why is it important and how often is it done? Journal Of Psychopharmacology 2010, 25: 1269-1276. PMID: 21169392, PMCID: PMC3256572, DOI: 10.1177/0269881110389347.Peer-Reviewed Original ResearchConceptsSmoking statusImpact of smokingEffect of smokingNeurobiology of depressionAntidepressant treatment outcomeAntidepressant drug responsePharmacological intervention studiesPharmacological trialsClinical trialsTreatment outcomesMEDLINE searchNicotine dependenceSmokingTargeted treatmentIntervention studiesTreatment studiesDrug responseDepressionOutcomesTreatment researchTrialsStatusTreatmentAntidepressantsPharmacotherapyInclusion of Women and Gender-Specific Analyses in Randomized Clinical Trials of Treatments for Depression
Weinberger AH, McKee SA, Mazure CM. Inclusion of Women and Gender-Specific Analyses in Randomized Clinical Trials of Treatments for Depression. Journal Of Women's Health 2010, 19: 1727-1732. PMID: 20799923, PMCID: PMC2936499, DOI: 10.1089/jwh.2009.1784.Peer-Reviewed Original ResearchConceptsRecent randomized clinical trialsRandomized clinical trialsClinical trialsGender-specific analysisDepression treatmentHealth (NIH) Revitalization ActCost of depressionInterventional studyInclusion of womenHigh prevalenceTreatment responseMEDLINE searchTreatment efficacyGender differencesPossible gender differencesDepression researchTrialsWomenDepressionNational InstituteRevitalization ActTreatmentFemale participantsOutcomesGender
1998
Acute Neuroleptic Treatment in Elderly Patients Without Dementia
Mazure C, Nelson J, Jatlow P, Bowers M. Acute Neuroleptic Treatment in Elderly Patients Without Dementia. American Journal Of Geriatric Psychiatry 1998, 6: 221-229. PMID: 9659955, DOI: 10.1097/00019442-199800630-00005.Peer-Reviewed Original ResearchConceptsNon-elderly adultsElderly patientsNeuroleptic treatmentAcute responseLow dosesLow-dose neuroleptic treatmentAcute neuroleptic treatmentAdverse effectsHigh-dose treatmentLow-dose treatmentDrug blood levelsPrimary psychotic illnessInitial doseBlood levelsPsychotic illnessEffective treatmentPatientsDose ratioLonger durationTreatmentLower ratesDosesAdultsResponseNeurolepticsManagement of the Adverse Effects of Clozapine
Young CR, Bowers MB, Mazure CM. Management of the Adverse Effects of Clozapine. Schizophrenia Bulletin 1998, 24: 381-390. PMID: 9718630, DOI: 10.1093/oxfordjournals.schbul.a033333.Peer-Reviewed Original ResearchConceptsAdverse effectsElevated liver enzymesPercent of patientsSuccessful pharmacological managementPositive therapeutic outcomesHypothesized pathophysiologyPharmacological managementRefractory schizophreniaNeuromuscular effectsTraditional neurolepticsLiver enzymesPharmacological interventionsClozapineAffective disordersTherapeutic outcomesNeurological disordersMental disordersMaximum doseObsessive-compulsive symptomsWeight gainDisordersPatientsPathophysiologyNew hopeTreatment
1997
The Expanding Indications for Clozapine
Young C, Longhurst J, Bowers M, Mazure C. The Expanding Indications for Clozapine. Experimental And Clinical Psychopharmacology 1997, 5: 216-234. PMID: 9260069, DOI: 10.1037/1064-1297.5.3.216.Peer-Reviewed Original ResearchConceptsUnique pharmacodynamic profileUse of clozapineTreatment-resistant schizophreniaTraditional drug treatmentExpanding IndicationsClozapine treatmentNeurologic conditionsPharmacodynamic profileClinical indicationsDrug treatmentMood disordersEffective treatmentClozapineSubstance abuseChildhood schizophreniaRelevant literatureSchizophreniaDisordersTreatmentAggressive behaviorIndicationsInitial rationaleAgranulocytosisPatientsBody of literature
1995
Desipramine Treatment of Major Depression in Patients Over 75 Years of Age
Nelson J, Mazure C, Jatlow P. Desipramine Treatment of Major Depression in Patients Over 75 Years of Age. Journal Of Clinical Psychopharmacology 1995, 15: 99-105.. PMID: 7782495, DOI: 10.1097/00004714-199504000-00004.Peer-Reviewed Original ResearchConceptsYounger patientsYears of ageElderly patientsMajor depressionDesipramine concentrationsDrug treatmentPatient trialsAdverse reaction rateMore effective drug treatmentsEffective drug treatmentUnipolar major depressionDesipramine treatmentDepressed patientsComparable dosesPatientsSide effectsResponse rateSimilar durationTrialsSecond trialTreatmentLower ratesBloodDepressionAge
1992
Lithium in combination with perphenazine: effect on plasma monoamine metabolites
Bowers M, Mazure C, Nelson J, Jatlow P. Lithium in combination with perphenazine: effect on plasma monoamine metabolites. Biological Psychiatry 1992, 32: 1102-1107. PMID: 1477190, DOI: 10.1016/0006-3223(92)90190-b.Peer-Reviewed Original ResearchDrug-responsive symptoms during early neuroleptic treatment
Mazure C, Nelson J, Jatlow P, Bowers M. Drug-responsive symptoms during early neuroleptic treatment. Psychiatry Research 1992, 41: 147-154. PMID: 1574541, DOI: 10.1016/0165-1781(92)90106-d.Peer-Reviewed Original ResearchConceptsDrug responseEarly drug responseDays of treatmentIdentification of symptomsNeuroleptic treatmentSerum concentrationsNeuroleptic drugsNeurochemical mechanismsPositive symptomsSymptomsProgressive phaseDrug actionConceptual disorganizationMultiple regression analysisRegression analysisTreatmentPsychosisSeverityHallucinationsResponse
1991
A Preliminary, Open Study of the Combination of Fluoxetine and Desipramine for Rapid Treatment of Major Depression
Nelson JC, Mazure CM, Bowers MB, Jatlow PI. A Preliminary, Open Study of the Combination of Fluoxetine and Desipramine for Rapid Treatment of Major Depression. JAMA Psychiatry 1991, 48: 303-307. PMID: 2009031, DOI: 10.1001/archpsyc.1991.01810280019002.Peer-Reviewed Original ResearchConceptsMajor depressionMean changeHamilton Depression Rating Scale scoresDepression Rating Scale scoresCombination of fluoxetineDesipramine plasma levelsRating Scale scoresBeta-adrenergic receptorsOpen studyDesipramine levelsPlasma levelsStandardized doseScale scoreDesipramineDesipramine hydrochlorideRapid treatmentPatientsFluoxetineDrugsWeeksDepressionInpatientsTreatmentRecent studiesSame setting
1984
Drug-Responsive Symptoms in Melancholia
Nelson J, Mazure C, Quinlan D, Jatlow P. Drug-Responsive Symptoms in Melancholia. JAMA Psychiatry 1984, 41: 663-668. PMID: 6732425, DOI: 10.1001/archpsyc.1984.01790180033004.Peer-Reviewed Original ResearchConceptsPlasma desipramine concentrationsTricyclic antidepressant treatmentHamilton Depression ScalePretreatment symptom severityAntidepressant treatmentDesipramine treatmentDesipramine concentrationsDepression ScaleDepressive symptomsSymptomsSymptom severityDesipramine hydrochlorideDrug responseMultiple regression analysisPatientsRegression analysisTreatmentMelancholia